Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $27.43.
A number of brokerages have issued reports on EXEL. JMP Securities upped their price objective on shares of Exelixis from $27.00 to $29.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 7th. Stephens began coverage on shares of Exelixis in a research report on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Exelixis in a research report on Friday, May 3rd. Truist Financial reaffirmed a “buy” rating and issued a $33.00 price objective (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $27.00 price objective on shares of Exelixis in a research report on Wednesday, August 7th.
Read Our Latest Stock Report on EXEL
Insider Activity at Exelixis
Institutional Trading of Exelixis
Institutional investors and hedge funds have recently bought and sold shares of the company. Fisher Asset Management LLC lifted its stake in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares in the last quarter. GAMMA Investing LLC purchased a new stake in Exelixis in the 4th quarter worth approximately $27,000. Rise Advisors LLC purchased a new stake in Exelixis in the 1st quarter worth approximately $28,000. Park Place Capital Corp purchased a new stake in Exelixis in the 2nd quarter worth approximately $45,000. Finally, USA Financial Formulas lifted its stake in Exelixis by 1,548.0% in the 4th quarter. USA Financial Formulas now owns 2,060 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,935 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.
Exelixis Price Performance
NASDAQ:EXEL opened at $26.93 on Thursday. Exelixis has a one year low of $18.64 and a one year high of $27.53. The firm has a 50-day moving average of $22.79 and a 200-day moving average of $22.35. The company has a market cap of $8.17 billion, a PE ratio of 42.08, a PEG ratio of 0.60 and a beta of 0.54.
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
See Also
- Five stocks we like better than Exelixis
- Where to Find Earnings Call Transcripts
- How to Invest in Silver: A Beginner’s Guide
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- How to Capture the Benefits of Dividend Increases
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.